MME and chronic kidney disease: Two novel therapeutic groups have recently emerged offering new tools for reducing residual renal and cardiac risk in non-dialysis CKD patients: angiotensin receptor–neprilysin inhibitors (ARNI) and sodium–glucose cotransporter two inhibitors (SGLT2i).